Our findings indicate that 2HG and Glx are potential noninvasive surrogate biomarkers for detecting IDH mutations, which has significant clinical implications for prognostication and implementation of appropriate clinical management procedures in glioma patients. This evidence concerns the gene IDH1 and central nervous system cancer.